Compare Nerdwallet Inc (NRDS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Novo Nordisk A/S — how do they compare? Nerdwallet Inc trades at $9.74 (market cap $625.17M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 264.4× Nerdwallet Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Novo Nordisk A/S for 116 Days on average.
| NRDS | NVO | |
|---|---|---|
Market Cap | $625.17M | $165.31B |
Volume | 1,321,316 | 11,432,838 |
Sector | Media | Health |
52-Week High | $15.93 | $63.98 |
52-Week Low | $7.58 | $35.29 |
Typical Hold Time | 45 Days | 116 Days |
Enterprise Value | $539.47M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.79, up 7.76% in 24 hours, with a bullish technical signal and strong profitability metrics including a 93.5% gross margin and 18.16% ROE. Recent earnings showed a Q2 2026 miss but beats in prior quarters, while revenue growth is robust, rising from $539M in 2022 to $837M in 2025. Positive cash flow trends and analyst consensus support a favorable outlook.
The stock presents a compelling value with a P/E of 10.87 and P/S of 0.81, though risks include reliance on organic search traffic and economic sensitivity. Analyst sentiment is bullish with 67% buy ratings, targeting upside potential. Continued execution on revenue growth and margin expansion are key catalysts for further gains.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
